1. Sweden Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Active Biotech AB

Active Biotech AB

3.20
SEK
-2.26
(-41.48%)
-1.95EPS
113.35MMarket Cap
Nov 05Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
25.95
2.45
3.49
4.08
4.3
3.78
0.75
1.23
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-50.89
-54.6
-41.55
-12.76
-23.09
-6.96
-7.26
-5.91
-7.5
-8.04
-6.04
-7.44
-2.77
- -
Free Cash Flow per Basic Share
-24.55
-63.44
-46.78
-15.67
-9.86
-7.67
-7.62
-5.91
-6.95
-7.59
-6.04
-7.63
-2.4
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
97.95
103.73
38.52
36.77
15.65
15.7
9.61
4.71
6.62
4.19
3.04
2.44
2.11
- -
Tangible Book Value per Share
97.95
103.73
38.52
36.77
15.65
15.7
9.61
4.71
6.62
4.16
3.01
2.42
2.1
- -
Basic Weighted Avg Shares
4
4
5
5
5
5
5
5
7
7
8
5
13
21
Sales/Revenue/Turnover
108
10
16
19
20
20
4
7
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-200.52
-2,196.94
-1,093.25
-289.49
-243.4
-148.83
-1,051.3
-480.39
- -
- -
- -
- -
- -
- -
Depreciation Expense
13
12
12
12
57
- -
1
1
1
1
2
2
2
- -
Net Income, GAAP
-212
-232
-194
-60
-109
-37
-34
-32
-50
-58
-46
-39
-37
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-196.11
-2,226.29
-1,189.13
-312.91
-537.36
-183.92
-965.27
-479.48
- -
- -
- -
- -
- -
- -
Working Capital
248
246
67
61
76
87
53
21
46
32
28
30
53
- -
LT Debt
224
223
216
207
- -
- -
2
1
- -
4
3
2
- -
- -
Total Equity
405
405
181
183
78
88
54
22
47
35
31
33
56
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-56.91
-57.11
-66.06
-32.81
-83.61
-44.54
-48.18
-84.97
-144.87
-143.8
-140.54
-124.26
-84.48
- -

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
26
26
26
Market Capitalization
120
113
152

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
68
56
- -
Cash, Cash Equivalents & STI
65
53
- -
Accounts Receivable, Net
3
3
- -
Inventories
- -
- -
- -
Total Current Liabilities
14
11
- -
Payables & Accruals
- -
- -
- -
ST Debt
2
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.96%
30.1%
69.85%
Free Cash Flow
-12.32%
2.84%
-19.83%
Net Income, GAAP
-3.48%
6.18%
-5.27%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.04
-1.05
-0.79
-1.36
-7.44
2025
-0.71
-0.91
-0.39
-0.54
-2.77
2026
-0.32
- -
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Helén Tuvesson
Full Time Employees
5
Sector
Health technology
Industry
Biotechnology
Address
Scheelevägen 22 Lund SN Sweden 223 63
IPO Date
Dec 19, 2003
Website
activebiotech.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Active Biotech AB (publ) is a Sweden-based biotechnology company specializing in the research, development, and production of pharmaceutical products focused on immunomodulatory treatments for oncology and inflammatory diseases. Its main products include small molecule immunomodulators such as tasquinimod and laquinimod, addressing hematological cancers, non-infectious uveitis, and solid tumors, alongside antibody-based immunotherapy represented by the partnered anti-cancer immunotherapy naptumomab with NeoTX Therapeutics. The company operates primarily in Sweden and collaborates internationally with academic and clinical partners in the US and Europe to advance its clinical programs. Founded in 1983 and headquartered in Lund, Sweden, Active Biotech's portfolio targets specialist indications with high medical need and commercial value. Recent major developments include the acquisition of exclusive rights to patents for tasquinimod in combination therapy for multiple myeloma, approval of a clinical trial for tasquinimod in myelofibrosis in Europe, and the start of enrollment for a clinical phase I study of a topical ophthalmic formulation of laquinimod. The company also completed a SEK 43.4 million rights issue in 2024 to support its clinical development activities and expanded its collaborations with institutions such as MD Anderson and Oncode Institute, while demonstrating clinical activity of naptumomab in non-small cell lung cancer. These advancements underline Active Biotech's strategic focus on innovative immuno-oncological and immunological therapies with significant unmet medical needs and projected commercial potential.